|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Angel Medical Systems |
|---|---|
| Collaborator: |
Symbios Clinical |
| Information provided by (Responsible Party): | Angel Medical Systems |
| ClinicalTrials.gov Identifier: | NCT00781118 |
Purpose
A prospective, randomized multicenter study of subjects with a high-risk of having a myocardial infarction (MI) due to acute coronary syndrome or bypass surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Myocardial Infarction (AMI) Coronary Occlusion Acute Coronary Syndrome |
Device: AngelMed Guardian System |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | AngelMed for Early Recognition and Treatment of STEMI |
| Estimated Enrollment: | 1020 |
| Study Start Date: | December 2008 |
| Estimated Study Completion Date: | May 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment
Alerting will be turned "ON" during Initial Programming at 7-14 Day visit. Subjects will be trained on the use of the Guardian System at the 7-14 Day Visit and be provided refresher courses at subsequent follow-up visits.
|
Device: AngelMed Guardian System
An implantable heart monitoring device that detects and alerts subjects to rapidly progressive ST shifts that might be indicative of thrombotic coronary occlusions. Components include Programmable monitoring device (IMD), Right Ventricle Lead, Lead Adapter, External Alarm Device (EXD) and a programmer.
|
|
Control
Subjects will receive standard of care. From the 7-14 Day Visit through 6 month follow-up visit alerting will be turned "OFF". At initial 6 month follow-up visit alerting will be turned "ON" and subjects will be trained on the use of the Guardian System.
|
Device: AngelMed Guardian System
An implantable heart monitoring device that detects and alerts subjects to rapidly progressive ST shifts that might be indicative of thrombotic coronary occlusions. Components include Programmable monitoring device (IMD), Right Ventricle Lead, Lead Adapter, External Alarm Device (EXD) and a programmer.
|
There are over one million acute myocardial infarctions (AMI) each year in the United States with more than 400,000 of these resulting in death. Early identification of AMI, and prompt treatment has been shown to significantly improve clinical outcomes. Experimental and clinical studies have shown that most of the irreversible damage to the myocardium occurs during the first two hours after coronary occlusion. Milavetz et al. demonstrated that successful reperfusion therapy within two hours was associated with the greatest degree of myocardial salvage. According to Boersma, et al., restoration of flow, regardless of the method used, can abort infarction within the first 30 minutes after coronary occlusion, and the benefit of fibrinolytic therapy compared with placebo is considerably higher in patients treated within 2 hours after symptom onset than in those treated later.2 Further, evidence exists that expeditious restoration of flow in the obstructed infarct artery after the onset of symptoms in patients with the most severe type of MI, ST elevation MI (STEMI) is a key determinant of short and long-term outcomes regardless of whether reperfusion is accomplished by fibrinolysis or percutaneous coronary intervention (PCI). , , Therefore, the early arrival at the hospital for a reliable diagnosis and initiation of treatment is paramount to improve the outcomes of myocardial infarction. However, despite efforts at educating the public over the past decade, the mean time from AMI symptom onset to arrival at a hospital for treatment has remained, disappointingly, at 2.5-3.0 hours.1,4,7
The largest proportion of the total pre-hospital delay is the interval between the onset of symptoms and the decision to seek medical treatment. Finnegan et al. described that the reasons for delay in seeking medical evaluation generally stem from patient misconceptions about symptom experience, expectations, and attribution. In many cases, patients expect the type of heart attack that they often see in movies or on television: the kind of crushing chest pain that drops a person to the ground. The reality is that many heart attacks are much "quieter," causing only mild chest pain or discomfort or other symptoms such as shortness of breath or diaphoresis.
If patients would take action during the first hour following symptom onset, many lives and significant cost could be saved. It is technically possible to monitor EKGs and detect an acute infarction, even if the patient is unaware that he or she is experiencing a heart attack. However, currently available systems have limitations in the home environment. Twelve lead EKG systems require a clinically trained individual to place them. Holter monitors suffer from limitations in the ability to detect ST deviation due to low compliance and are limited in practice to 24 to 72 hours of monitoring. Systems using surface leads are all subject to noise and other artifacts from patient movement and body orientation, particularly if the patient is ambulatory.
A potentially ideal solution is to implant a device that measures heart signals from inside the heart and will alert the patient when it detects electrogram characteristics set by the physician as worthy of medical evaluation.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subject has at least one of the following conditions:
Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following:
Exclusion Criteria:
Contacts and Locations| Contact: David Keenan | 732-542-3350 | dkeenan@angel-med.com |
Show 65 Study Locations
More Information
| Responsible Party: | Angel Medical Systems |
| ClinicalTrials.gov Identifier: | NCT00781118 History of Changes |
| Other Study ID Numbers: | ALERTS Study |
| Study First Received: | October 24, 2008 |
| Last Updated: | May 23, 2012 |
| Health Authority: | United States: Food and Drug Administration |
|
Acute Myocardial Infarction (MI) ST Shift Coronary Occlusion Acute Coronary Syndrome |
|
Infarction Myocardial Infarction Coronary Occlusion Acute Coronary Syndrome Ischemia Pathologic Processes Necrosis Myocardial Ischemia |
Heart Diseases Cardiovascular Diseases Vascular Diseases Coronary Disease Angina Pectoris Chest Pain Pain Signs and Symptoms |